MedTrace Logo

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-05-14

No results posted yet for this study

Summary

To determine the effect of Essential Fatty Acids (EFA's) on Meibomian Gland lipids and aqueous tear production in patients with "dry eyes".

Conditions

  • Dry Eye Syndrome

Interventions

DIETARY_SUPPLEMENT

Omega-3 fatty acid supplement

Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.

DIETARY_SUPPLEMENT

Placebo

Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.

Sponsors & Collaborators

  • Advanced Vision Research

    collaborator INDUSTRY

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • James P. McCulley, M.D. · University of Texas, Southwestern Medical Center at Dallas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00344721 on ClinicalTrials.gov